natgillin/translations-raw huggingface dataset:
the Direct Healthcare Professional Communication (DHPC) on the association of Silodosin with Intraoperative Floppy Iris Syndrome and the two literature references mentioned in the text of the communication (at launch);
Neposredno obvestilo za zdravstvene delavce (DHPC) o povezavi zdravilne učinkovine silodozin z medoperacijskim sindromom ohlapne šarenice in dve referenci v literaturi, omenjeni v besedilu obvestila (ob začetku prodaje);
The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (↔), below (↓) or above (↑) the 80-125% range.
Smer puščice je za vsak farmakokinetični parameter določena na osnovi 90% intervala zaupanja geometričnega povprečnega razmerja, ki je znotraj (↔), pod (↓) ali nad (↑) območjem 80-125% spremembe.
The direction of the arrow indicates the direction of the change in exposures (Cmax, and AUC) in paritaprevir, ombitasvir, dasabuvir and the co-administered medicinal product (↑ = increase (more than 20%), ↓ = decrease (of more than 20%), ↔ = no change or change less than 20%).
Smer puščice kaže smer spremembe izpostavljenosti (Cmax in AUC) paritaprevirju, ombitasvirju, dasabuvirju in sočasno uporabljenemu zdravilu (↑ = povečanje za več kot 20 %, ↓ = zmanjšanje za več kot 20 %, ↔ = brez spremembe ali sprememba manj kot 20 %).
The directions regarding needle handling are not intended to replace local, healthcare professional and/or institutional policies.
Navodila glede ravnanja z iglami ne nadomeščajo lokalnih smernic, smernic zdravstvenega osebja in/ali ustanov.
The directions regarding needle handling are not intended to replace local, healthcare professional or institutional policies.
Navodila za ravnanje z iglami niso namenjena temu, da bi nadomestila lokalne smernice, smernice zdravstvenih delavcev ali ustanov.
The directions regarding needle handling are not intended to replace local, healthcare professional, or institutional policies.
Navodila za ravnanje z iglami nimajo namena nadomestiti lokalnih smernic, smernic zdravstvenih delavcev ali smernic ustanov.
The directions regarding syringe handling and disposal are not intended to replace local or institutional policies.
Navodila za ravnanje z injekcijskimi brizgami in za njihovo odlaganje niso namenjena temu, da bi nadomestila lokalne smernice ali smernice zdravstvenih ustanov.
The disappearance of desirudin from plasma is rapid in the first phase with approximately 90% of an intravenous (IV) bolus dose disappearing from the circulation within 2 hours of the injection.
V prvi fazi je izginjanje desirudina iz plazme hitro: približno 90% intravenskega (i.v.) bolusnega odmerka izgine iz obtoka v 2 urah po injekciji.
The discontinuation rate due to adverse reactions 3.5 %, 3.4 % and 4.0 % for patients randomized to brivaracetam at respectively the dose of 50 mg/day, 100 mg/day and 200 mg/day and 1.7 % for patients randomized to placebo.
Stopnja prekinitve zdravljenja zaradi neželenih učinkov je bila 3,5 %, 3,4 % in 4,0 % pri bolnikih, randomiziranih na brivaracetam z odmerki 50 mg/dan, 100 mg/dan in 200 mg/dan, in 1,7 % pri bolnikih, ki so bili randomizirani na zdravljenje s placebom.
The discontinuation rate due to adverse reactions was 3.5 %, 3.4 % and 4.0 % for patients randomized to brivaracetam at respectively the dose of 50 mg/day, 100 mg/day and 200 mg/day and 1.7 % for patients randomized to placebo.
Stopnja prekinitve zdravljenja zaradi neželenih učinkov je bila 3,5 %, 3,4 % in 4,0 % pri bolnikih, randomiziranih na brivaracetam z odmerki 50 mg/dan, 100 mg/dan in 200 mg/dan, in 1,7 % pri bolnikih, ki so bili randomizirani na zdravljenje s placebom.
The discontinuation rate due to injection site reactions was 0.7% in the 300 mg once every 4 weeks treatment group and 0% in the placebo group.
Delež prekinitev zaradi reakcij na mestu injiciranja je bil v skupini s 300 mg enkrat na 4 tedne 0,7 % in v skupini s placebom 0 %.
the disease being treated
bolezni, ki se zdravi;
the disease being treated
zdravljene bolezni,
the disease being treated,
zdravljene bolezni,
the disease being treated.
bolezen, zaradi katere se zdravite.
The disease can appear at birth (the ‘infantile-onset’ form) but also later in life (the ‘late-onset’ form).
Bolezen se lahko pojavi ob rojstvu („zgodnji nastop“ bolezni), pa tudi kasneje v življenju („pozni nastop“ bolezni).
The disease can cause a change in the shape of the erect penis due to the abnormal buildup of scar tissue, known as a plaque, within the stretchy fibres of the penis.
Bolezen lahko povzroči spremmbo oblike penisa med erekcijo zaradi nenormalnega kopičenja brazgotinastega tkiva, znanega kot plak, v raztegljivih vlaknih penisa.
The disease characteristics of the overall study population were metastatic disease in 98% of patients, 92% of patients’ tumours were classified as adenocarcinoma histology, and 27% of patients had brain metastases.
Značilnosti bolezni v celotni študijski populaciji so bile: metastatska bolezen pri 98 % bolnikov, 92 % tumorjev bolnikov, histološko razvrščenih med adenokarcinome, in 27 % bolnikov z možganskimi metastazami.
The disease characteristics were 91% metastatic, 96% adenocarcinoma histology, and 13% with no prior systemic therapy for metastatic disease.
Značilnosti bolezni so bile naslednje: 91 % metastatski primeri, 96 % histološko razvrščenih med adenokarcinome in 13 % brez predhodnega sistemskega zdravljenja metastatske bolezni.
The disease control rate (complete response plus partial response plus stable disease) was numerically higher in patients on the ramucirumab plus FOLFIRI arm as compared to the placebo plus FOLFIRI arm (74.1% versus 68.8%, respectively).
Stopnja nadzorovanja bolezni (popoln odziv in delni odziv in stabilna bolezen) je bila številčno višja pri bolnikih, ki so se zdravili v skupini z ramucirumabom in shemo FOLFIRI, v primerjavi s skupino s placebom in shemo FOLFIRI (74,1 % v primerjavi z 68,8 %).
The disease control rate (DCR) (defined as CR+PR+SD) was 75% (6/8 patients) and 0%, respectively.
Delež nadzorovane bolezni (opredeljena kot popoln odziv + delni odziv + stabilna bolezen) je bil v skupini, ki je prejemala ipilimumab kot monoterapijo 75 % (6/8 bolnikov), v skupini, ki je prejemala samo gp100 pa 0 %.
The disease is serious and has a high death rate.
Bolezen je resna, smrtnost pri njej pa visoka.
the disease to which the product is intended to confer immunity is largely absent from the territory in question
bolezen, za katero se z zdravilom pridobi imunost, na zadevnem območju skoraj ni prisotna.
the disease to which the product is intended to confer immunity is largely absent from the territory in question.
bolezen, za katero se pridobi imunost, na območju skoraj ni prisotna.
the disease to which the product is intended to confer immunity is largely absent from the territory in question.
bolezen, za katero se z zdravilom pridobi imunost, na območju skoraj ni prisotna.
The disease to which the product is intended to confer immunity is largely absent from the territory in question.
Bolezen, za katero se z zdravilom pridobi imunost, na zadevnem območju skoraj ni prisotna
the disease to which the product is intended to confer immunity is largely absent from the territory in question.
bolezen, za katero se z zdravilom pridobi imunost, na zadevnem območju skoraj ni prisotna. >
the disease to which the product is intended to confer immunity is largely absent from the territory in question.
bolezen, za katero se z zdravilom za uporabo v veterinarski medicini pridobi imunost, na območju skoraj ni prisotna.
the disease to which the product is intended to confer immunity is largely absent from the territory.
bolezni, za katero se z izdelkom pridobi imunost, na območju skoraj ni.
the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.
bolezen, za katero se z zdravilom za uporabo v veterinarski medicini pridobi imunost, na območju skoraj ni prisotna.
The diseases cause the gradual loss of the central part of a person’s vision.
Bolezen povzroči postopno izgubo osrednjega dela vida.
The dispensing and storage directions below are specific to aldesleukin.
Spodaj opisana navodila za odmerjanje in shranjevanje so specifična za aldeslevkin.
The dispersible tablets are only for use in patients who cannot take the film-coated tablets.
Disperzibilne tablete so namenjene samo bolnikom, ki ne morejo jemati filmsko obloženih tablet.
The dispersible tablets are to be mixed with a liquid to make up a suspension that the patient can drink.
Disperzibilne tablete se s tekočino zmešajo v suspenzijo, ki jo bolnik lahko spije.
The dispersible tablets contain lactose.
Disperzibilne tablete vsebujejo laktozo.
The dispersible tablets have score lines so that they can be broken into quarters, each containing 8 mg bosentan.
Disperzibilne tablete imajo zareze, da se jih lahko razlomi na četrtine, od katerih vsaka vsebuje 8 mg bosentana.
The dispersible tablets must not be broken or crushed.
Tablet se ne sme lomiti ali drobiti.
The dispersible tablets should be taken on an empty stomach (at least 30 minutes before food) whereas the film-coated tablets can be taken with a light meal.
Disperzibilne tablete je treba jemati na prazen želodec (vsaj 30 minut po zaužitju hrane), filmsko obložene tablete pa je mogoče vzeti z lahkim obrokom.
The dispersion can also be administered through a gastric tube.
Disperzijo je možno dajati z želodčno sondo.
The dispersion is slightly cloudy, with a cream-to-pink colour.
Rahlo motna disperzija kremasto do rožnate barve.
The dispersion should be withdrawn from the vial using a syringe with a 18 to 20 gauge sterile needle or attached to a sterile non-siliconised mini-spike.
Disperzijo morate izvleči iz viale z brizgo, ki ima nameščeno sterilno iglo številka 18 do 20 ali sterilno nesilikonizirano mini-konico.
The display now shows ‘P3’ and the lock symbol.
Na zaslonu se bosta prikazala oznaka »P3« in simbol ključavnice.
The display now shows ‘P4’ and a lock symbol appears.
Na zaslonu se bosta sedaj prikazala oznaka »P4« in simbol ključavnice.
The display will now turn on and show ‘P5’.
Zaslon se bo sedaj aktiviral in prikazala se bo oznaka »P5«.
The displayed frequency categories use the following convention: very common (1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Kategorije pogostnosti so opredeljene v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The displayed frequency categories use the following convention: very common (1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Kategorije pogostnosti so opredeljene v skladu z naslednjim dogovorom:: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The displayed frequency categories use the following convention: very common (1/10); common (1/100 to <1/10); uncommon (1/1000 to <1/100); rare (1/10,000 to <1/1000); very rare (<1/10,000); not known (cannot be estimated from the available clinical trial data).
V skladu z dogovorom so neželeni učinki opredeljeni po pogostnosti kot: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The disposition of ONIVYDE and non-liposomal irinotecan has not been fully elucidated in humans.
Odstranjevanje zdravila ONIVYDE in neliposomskega irinotekana pri človeku še ni popolnoma pojasnjeno.
The dissolution of the contents is achieved by slow turning (avoid froth formation due to shaking).
Vsebino raztopite tako, da vialo počasi obračate (pazite, da ne bo nastala pena zaradi stresanja).
The dissolved eschar must be removed from the wound by wiping it away with a sterile blunt- edged instrument.
Odluščene eshare morate odstraniti z rane tako, da jih obrišete s sterilnim topim inštrumentom.
The dissolved Rilonacept Regeneron solution should be a thick, clear liquid, colourless to pale yellow.
Raztopljena raztopina zdravila Rilonacept Regeneron mora biti gosta, bistra tekočina, brezbarvna do bledo rumene barve.
The distribution and clearance of cytarabine and of the predominant phospholipid component of the lipid particle (DOPC) following intrathecal administration of DepoCyte was evaluated in rodents.
Pri glodalcih so ocenili porazdelitev in očistek citarabina in prevladujoče fosfolipidne komponente lipidnega delca (DOPC) po intratekalnem dajanju zdravila DepoCyte.
The distribution and mineral concentrations in the organs were investigated at low (9-10 mg/kg) and high (19-20 mg/kg) doses administered intravenously to rats.
Porazdelitev in mineralne koncentracije v organih so proučevali pri nizkih (9–10 mg/kg) in visokih (19–20 mg/kg) odmerkih, ki so jih podganam dali intravensko.
The distribution of ambrisentan into red blood cells is low, with a mean blood:plasma ratio of 0.57 and
Porazdelitev ambrisentana v eritrocite je majhna.
The distribution of body weight and age, two covariates impacting alirocumab exposure, were different among renal function categories and most likely explain the observed pharmacokinetic differences.
Porazdelitev telesne mase in starosti – ki obe vplivata na izpostavljenost alirokumabu – sta se med obema kategorijama delovanja ledvic razlikovali; to najverjetneje pojasni opažene farmakokinetične razlike.
The distribution of CE and bazedoxifene after administration of CE/bazedoxifene has not been studied.
Porazdelitve CE in bazedoksifena po uporabi kombinacije CE/bazedoksifena niso raziskovali.
The distribution of patients by age and minimum, median and maximum dose received during the OL LI phase is presented in Table 4.
Preglednica 4 prikazuje porazdelitev bolnikov po starosti ter najmanjšem, srednjem in največjem odmerku, prejetem med odprto uvajalno fazo.
The distribution of patients by age and minimum, median and maximum dose received during the OL LI phase is presented in Table 6.
Preglednica 6 prikazuje porazdelitev bolnikov po starosti ter najmanjšem, srednjem in največjem odmerku, prejetem med odprto uvajalno fazo.
The distribution of patients by age and minimum, median and maximum dose received during the OL LI phase is presented in Table 8.
Preglednica 8 prikazuje porazdelitev bolnikov po starosti ter najmanjšem, srednjem in največjem odmerku, prejetem med odprto uvajalno fazo.
The distribution of subjects by gender was 60% men and 40% women.
Porazdelitev preiskovancev po spolu je bila: 60 % moških in 40 % žensk.
The distribution of subjects by gender was 67% men and 33% women.
Porazdelitev preiskovancev po spolu je bila: 67 % moških in 33 % žensk.
The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3.
Na porazdelitev alafenamidtenofovirata v telesu lahko vplivata dejavnost OATP1B1 in OATP1B3.
The distribution of the card will also prompt dialogue on any new or changes in symptoms since the prior visit.
Izročitev kartončka bo tudi spodbudila pogovor o pojavu kakršnihkoli novih simptomov ali o spremembi simptomov od prejšnjega obiska.
The distribution phase represents 31% ± 22% to 69% ± 15% (mean ± SD) of the total AUC following the administration of doses ranges from 5 to 50 mg .
Faza porazdelitve je 31 % ± 22 % do 69 % ± 15 % (srednja vrednost ± SD) skupne AUC po dajanju odmerkov v razponu 5 do 50 mg.
The distribution volume of both levodopa (Vd 0.36-1.6 l/kg) and entacapone (Vdss 0.27 l/kg) is moderately small while no data for carbidopa are available.
Volumen porazdelitve tako levodope (Vd 0,36 – 1,6 l/kg) kot entakapona (Vdss 0,27 l/kg) je zmerno majhen, medtem ko za karbidopo ni podatkov.
The distribution volume was in the range of the estimated plasma volume.
Volumen porazdelitve je bil v območju predvidenega plazemskega volumna.
The division of the daily dose may be adjusted on a physician’s advice taking into account the dietary intake of phosphate.
Razdelitev dnevnega odmerka se lahko prilagodi po nasvetu zdravnika ob upoštevanju vnosa fosfata s hrano.
The DLSM, 95% CI, and p-value are based on an ANCOVA (analysis of covariance) model adjusted for country and baseline ADAS-cog score.
Vrednosti razlik po metodi najmanjših kvadratov (DLSM), 95 % IZ in vrednosti p temeljijo na modelu ANCOVA (analizi kovariance) s prilagajanjem na državo in izhodiščno oceno pri lestvici ADAS-cog
The Docefrez 80 mg vial contains a white to off white lyophilised powder in a 15 ml tubular colourless glass vial with 20 mm grey rubber stopper and sealed with red flip-off aluminium seal.
Viala Docefrez 80 mg vsebuje bel do sivo bel liofoliziran prašek, v 15 ml cevasti brezbarvni viali z 20 mm sivim pokrovom in zaprto z rdečim aluminijastim tesnilom.
The Docetaxel 20 mg vial contains a solution of docetaxel in polysorbate 80 at a concentration of 27.73 mg/ml.
Viala z 20 mg docetaksela vsebuje raztopino docetaksela v polisorbatu 80 v koncentraciji 27,73 mg/ml.
The Docetaxel 20 mg/0.72 ml vial contains a solution of docetaxel in polysorbate 80 at a concentration of 27.73 mg/ml.
Docetaksel 20 mg/0,72 ml viala vsebuje raztopino docetaksela v polisorbatu 80 v koncentraciji 27,73 mg/ml.
The Docetaxel 20 mg/0.72 ml vial is a 6 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Docetaksel 20 mg/0,72 ml viala je 6 ml viala iz prozornega stekla z zaporko iz brombutilne gume in pokrovčkom Flip Off.
The Docetaxel 80 mg vial contains a solution of docetaxel in polysorbate 80 at a concentration of 27.73 mg/ml.
Viala z 80 mg docetaksela vsebuje raztopino docetaksela v polisorbatu 80 s koncentracijo 27,73 mg/ml.
The Docetaxel 80 mg vial is a 15 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Viala z 80 mg docetaksela je 15 ml viala iz prozornega stekla z zaporko iz brombutilne gume in pokrovčkom Flip Off.
The Docetaxel 80 mg/2.88 ml vial contains a solution of docetaxel in polysorbate 80 at a concentration of 27.73 mg/ml.
Docetaksel 80 mg/2,88 ml viala vsebuje raztopino docetaksela v polisorbatu 80 s koncentracijo 27,73 mg/ml.
The Docetaxel 80 mg/2.88 ml vial is a 15 ml clear glass vial with a bromobutyl rubber stopper and a flip-off cap.
Docetaksel 80 mg/2,88 ml viala je 15 ml viala iz prozornega stekla z zaporko iz brombutilne gume in pokrovčkom Flip Off.
The doctor calculates the dose for each patient individually depending on the patient’s condition.
Zdravnik za vsakega bolnika posebej izračuna ustrezni odmerek glede na njegovo zdravstveno stanje.
The doctor calculates the dose for each patient individually, depending on the body weight and the condition being treated.
Zdravnik za vsakega bolnika individualno izračuna odmerek na osnovi njegove telesne teže in zdravljene bolezni.
The doctor calculates your dose of Metalyse according to your bodyweight, based on the following scheme:
Zdravnik izračuna za vas ustrezen odmerek zdravila Metalyse na podlagi vaše telesne mase po naslednji shemi:
The doctor may adjust the dose depending on how patients respond to treatment.
Zdravnik lahko odmerek prilagodi glede na bolnikov odziv.
The doctor may adjust the dose of Ferriprox depending on the patient’s response, which should be measured every two to three months with blood tests.
Zdravnik lahko prilagodi odmerek zdravila Ferriprox glede na bolnikov odziv, ki ga je treba s krvnim testom izmeriti vsake dva do tri mesece.
The doctor may advise a lower dose, especially when starting treatment in certain patients such as those on hae modialysis, or those over the age of 75 years.
Nekaterim bolnikom, kot so bolniki, ki se zdravijo s hemodializo, in bolniki, starejši od 75 let, lahko zdravnik predpiše manjši odmerek, še posebej na začetku zdravljenja.
The doctor may advise the patient to take a fever-reducing painkiller before each injection and for 24 hours after injection to reduce the influenza (flu)-like symptoms that may occur as a side effect of treatment.
Zdravnik lahko bolniku svetuje, naj pred vsakim injiciranjem in 24 ur po njem vzame protibolečinsko sredstvo za zniževanje povišane telesne temperature, da se ublažijo gripi podobni simptomi, ki se lahko pojavijo kot neželeni učinek zdravljenja.
The doctor may continue to increase your dose at monthly intervals if necessary.
Če bo potrebno, bo lahko zdravnik nadaljeval s povečevanjem odmerka v mesečnih intervalih.
The doctor may decide to interrupt treatment or reduce the dose if signs of liver problems or other side effects develop.
Zdravnik lahko zdravljenje prekine ali zmanjša odmerek, če se pojavijo znaki težav z jetri ali drugi neželeni učinki.
The doctor may decide to perform a skin test to check the patient’s allergy status before prescribing the medicine.
Pred izdajo recepta za zdravilo se lahko zdravnik odloči za izvedbo kožnega preskusa, s katerim preveri alergijski status bolnika.
The doctor may delay, reduce or stop doses if the patient experiences certain side effects, including blood clots, nerve damage, rash, low heart rate, fainting or sleepiness.
Zdravnik lahko odmerke odloži, zmanjša ali ukine, če se pri bolniku pojavijo nekateri neželeni učinki, kot npr. krvni strdki, poškodbe živčevja, izpuščaji, počasen utrip srca, omedlevica ali zaspanost.
The doctor may give you a lower dose if they think you need it.
Zdravnik vam lahko da manjši odmerek, če misli, da ga potrebujete.
The doctor may have to adjust or
Pri bolnikih, ki imajo hude neželene učinke,
The doctor may have to check the condition of the child’s liver during treatment.
Zdravnik bo med zdravljenjem morda moral kontrolirati stanje otrokovih jeter.
The doctor may increase the dose depending on the patient’s response but the daily dose should not be higher than 24 mg buprenorphine.
Zdravnik bo v skladu z bolnikovim odzivom odmerek morda povečal, vendar pa dnevni odmerek ne sme presegati 24 mg buprenorfina.
The doctor may interrupt or stop treatment if the patient develops reactions linked to the infusion (such as rash, itchiness and difficulty breathing) or hypersensitivity (allergic) reactions which may be severe and life-threatening and can develop several hours after Benlysta is given.
Zdravnik lahko prekine ali zaustavi zdravljenje, če se pri bolniku pojavijo reakcije, povezane z infuzijo (npr. izpuščaji, srbenje in težave z dihanjem), ali preobčutljivostne (alergijske) reakcije, ki se lahko pojavijo nekaj ur po prejemu zdravila Benlysta.
The doctor may interrupt or stop treatment, or reduce the dose, if the patient develops certain serious side effects.
Če se pri bolniku pojavijo nekateri resni neželeni učinki, bo zdravnik morda moral začasno ali trajno prekiniti zdravljenje oziroma zmanjšati odmerek.
The doctor may need to adjust the dose by taking into account the patient’s age, liver or kidney function and certain side effects that the patient may be experiencing.
Zdravnik bo morda moral prilagoditi odmerek ob upoštevanju bolnikove starosti, delovanja jeter ali ledvic in nekaterih neželenih učinkov, ki bi se lahko pojavili pri bolniku.
The doctor may need to adjust the dose or change one of the medicines to something else:
Zdravnik bo morda moral odmerek prilagoditi ali spremeniti katero od izbranih zdravil:
The doctor may need to delay doses if certain side effects occur, or stop treatment
Zdravnik bo morda moral počakati z naslednjimi odmerki, če se pojavijo nekateri neželeni
The doctor may need to delay doses if certain side effects occur, or stop treatment altogether if side effects are severe.
Zdravnik bo morda počakal z naslednjimi odmerki, če se pojavijo nekateri neželeni učinki, ali popolnoma prekinil zdravljenje, če so neželeni učinki hudi.